These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38055233)

  • 1. The Consideration of Cyclosporine in the Treatment of Stevens-Johnson Syndrome.
    Malick H; Lauck K; Kivelevitch D
    JAMA Dermatol; 2024 Jan; 160(1):117. PubMed ID: 38055233
    [No Abstract]   [Full Text] [Related]  

  • 2. The Consideration of Cyclosporine in the Treatment of Stevens-Johnson Syndrome-Reply.
    Miyamoto Y; Ohbe H; Yasunaga H
    JAMA Dermatol; 2024 Jan; 160(1):117-118. PubMed ID: 38055234
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Gilbert M; Scherrer LA
    Dermatol Ther; 2019 Jan; 32(1):e12758. PubMed ID: 30285308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic epidermal necrolysis in a patient with psoriatic arthritis.
    Pace J; Adami JZ; Mallia C; Mizzi A
    Adv Exp Med Biol; 1999; 455():557-60. PubMed ID: 10599399
    [No Abstract]   [Full Text] [Related]  

  • 5. Pediatric SJS/TEN Subdued by a Combination of Dexamethasone, Cyclosporine, and Etanercept.
    Coulombe J; Belzile E; Duhamel A; Rault P; Buteau C; DeBruycker JJ; Bussières JF
    J Cutan Med Surg; 2019; 23(5):547-550. PubMed ID: 31478770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine in SJS/TEN management: a brief review.
    Shokeen D
    Cutis; 2016 Mar; 97(3):E17-8. PubMed ID: 27023091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous cyclosporine in treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: A case series.
    Vinay K; Kaushik A; Kumaran MS; Parsad D
    Dermatol Ther; 2019 Jul; 32(4):e12957. PubMed ID: 31070856
    [No Abstract]   [Full Text] [Related]  

  • 8. New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis.
    Roujeau JC; Mockenhaupt M; Guillaume JC; Revuz J
    J Invest Dermatol; 2017 Oct; 137(10):2047-2049. PubMed ID: 28941473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Blistering cutaneous lesions in a patient with systemic lupus erythematosis].
    Rodríguez M; Fernández-Espartero MC; Satué JA; de la Mata J
    Rev Clin Esp; 2001 May; 201(5):293-4. PubMed ID: 11458808
    [No Abstract]   [Full Text] [Related]  

  • 10. Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin.
    Zaki I; Patel S; Reed R; Dalziel KL
    Br J Dermatol; 1995 Aug; 133(2):337-8. PubMed ID: 7547417
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 vaccine-induced Stevens-Johnson syndrome.
    Dash S; Sirka CS; Mishra S; Viswan P
    Clin Exp Dermatol; 2021 Dec; 46(8):1615-1617. PubMed ID: 34081806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center.
    Lee HY; Fook-Chong S; Koh HY; Thirumoorthy T; Pang SM
    J Am Acad Dermatol; 2017 Jan; 76(1):106-113. PubMed ID: 27717620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.
    Kirchhof MG; Miliszewski MA; Sikora S; Papp A; Dutz JP
    J Am Acad Dermatol; 2014 Nov; 71(5):941-7. PubMed ID: 25087214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine in toxic epidermal necrolysis: a brief review of the emerging therapeutic modality.
    Kumar P; Kanti Das N
    Dermatol Online J; 2016 Oct; 22(10):. PubMed ID: 28329582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study.
    Mohanty S; Das A; Ghosh A; Sil A; Gharami RC; Bandyopadhyay D; Das NK
    Indian J Dermatol Venereol Leprol; 2017; 83(3):312-316. PubMed ID: 28366923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of intravenous immunoglobulins in a patient with systemic lupus erythematosus presenting with Stevens-Johnson syndrome.
    Vázquez-Sanabria IL; Mercado-Seda R; Varela-Rosario N; Vilá LM
    BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26202316
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid.
    Singh GK; Chatterjee M; Verma R
    Indian J Dermatol Venereol Leprol; 2013; 79(5):686-92. PubMed ID: 23974585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening.
    Fernando SL; Broadfoot AJ
    CMAJ; 2010 Mar; 182(5):476-80. PubMed ID: 19933789
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of cyclosporine for the treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Shah R; Chen ST; Kroshinsky D
    J Am Acad Dermatol; 2021 Aug; 85(2):512-513. PubMed ID: 30630021
    [No Abstract]   [Full Text] [Related]  

  • 20. Toxic Epidermal Necrolysis in a Boy: Successful Treatment With Cyclosporine A.
    Quintana-Castanedo L; Nieto-Rodríguez D; Rodríguez-Álvarez D; Feito-Rodríguez M; de Lucas-Laguna R
    Actas Dermosifiliogr (Engl Ed); 2021 May; 112(5):468-470. PubMed ID: 33253652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.